10/10/2023 - Reven Asks Court to Consider Additional Ongoing Harm to Company, IP and Shareholders from TRO and Asset Freeze.
Access Michael Volk's Declaration here

6/13/2023 - Reven hits back, opposing SEC’s motion for injunctive relief.
Read more here



Launching a new generation of pharmacological solutions that target the root cause of diseases by restoring immune system homeostasis.

RJX by Reven

RJX is a stand-alone drug and a flexible formulation developed with a proprietary process to target areas of immunologic function without the need for stabilizers and preservatives.

“Our goal is to impact multiple disease indications stemming from inflammation ranging from cancer to cardiovascular disease in the same way antibiotics impacted infectious disease when they were discovered nearly a century ago.”

Michael Volk / Co-Founder & CSO

Interested in learning more? Explore Reven I Join Reven

Reven Holdings, Inc. 2921 W. 120th Ave / Suite 220 Westminster, CO 80234

1-866-REVEN-RX (1-866-738-3679) info@reven.com

© 2021 Reven Holdings, Inc. — All rights reserved.